Arvinas, Inc. (NASDAQ:ARVN) CEO Sells $523,971.36 in Stock

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) CEO John G. Houston sold 31,338 shares of Arvinas stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the transaction, the chief executive officer now owns 1,157,480 shares in the company, valued at $19,353,065.60. The trade was a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Arvinas Trading Up 2.5 %

Shares of NASDAQ:ARVN traded up $0.44 during midday trading on Friday, hitting $17.70. The company had a trading volume of 932,873 shares, compared to its average volume of 1,027,486. Arvinas, Inc. has a 12 month low of $16.07 and a 12 month high of $51.51. The firm has a fifty day simple moving average of $18.37 and a 200 day simple moving average of $22.72. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -6.39 and a beta of 1.88.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping analysts' consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter in the previous year, the business earned ($2.53) EPS. Equities analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Institutional Trading of Arvinas

Hedge funds have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new position in Arvinas in the 4th quarter worth $28,000. KBC Group NV grew its holdings in shares of Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company's stock worth $55,000 after buying an additional 1,255 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company's stock valued at $61,000 after buying an additional 440 shares during the last quarter. Quantbot Technologies LP raised its position in Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock valued at $108,000 after buying an additional 2,601 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in Arvinas in the 4th quarter valued at approximately $171,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ARVN shares. Wedbush restated an "outperform" rating and issued a $57.00 price objective on shares of Arvinas in a research note on Tuesday, February 11th. Guggenheim reiterated a "buy" rating and set a $57.00 target price on shares of Arvinas in a research report on Wednesday, February 12th. BTIG Research assumed coverage on Arvinas in a research report on Tuesday, December 10th. They issued a "buy" rating and a $69.00 price target on the stock. Barclays dropped their price objective on shares of Arvinas from $48.00 to $32.00 and set an "overweight" rating for the company in a report on Monday, February 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $87.00 price target on shares of Arvinas in a report on Wednesday, December 11th. Twelve analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $60.00.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.